Microbicides: latest news

Microbicides resources

  • Microbicides

    Microbicides are any substances which protect people against infection by microbes, such as viruses or bacteria, on contact with those microbes....

    From: Preventing HIV

    Information level Level 4
  • Microbicides

    A microbicide is a topical agent that, when applied to a mucosal surface, serves as a barrier to infection. Microbicides can come in the form of...

    From: HIV transmission & testing

    Information level Level 4

Microbicides features

Microbicides news from aidsmap

More news

Microbicides news selected from other sources

  • Study: In two-drug, HIV-preventing vaginal ring, only one drug does the job

    The National Institutes of Health has shown that a study of its vaginal ring for the prevention of HIV came back with mixed results. The ring, which delivers two drugs, was safe for 28 days, but only one of the antiretroviral drugs was effective in protecting against the virus.

    10 March 2014 | Fierce Drug Delivery
  • New Rings, Gels, and Films Show Promise in Microbicide Trials

    Experimental vaginal microbicides—products such as gels, films, or flexible rings worn inside the vagina—were the focus of two studies reported Tuesday at the 21st Conference on Retroviruses and Opportunistic Infections.

    05 March 2014 | BETA blog
  • Study comparing injectable contraceptives DMPA and NET-EN finds HIV risk higher with DMPA

    Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE. The new analysis, conducted by researchers from the NIH-funded Microbicide Trials Network, is the first head-to-head observational study to directly compare differences in HIV risk between users of DMPA and NET-EN.

    04 March 2014 | Eurekalert Medicine & Health
  • Janssen Announces New Group Targeting Unmet Global Health Needs

    Janssen GPH will be responsible for clinical and product development and creating and implementing innovative new access strategies for a growing portfolio of pharmaceuticals, diagnostics, and services for diseases significantly impacting resource-limited countries and emerging markets, and includes bedaquiline for drug-resistant TB, long-lasting injectable rilpivirine for HIV prevention and the dapivirin ring for HIV prevention.

    22 January 2014 | Janssen press release
  • USAID, Population Council agreement for non-antiretroviral microbicide quest looks to expand prevention toolbox

    An agreement between the United States Agency for International Development and the Population Council announced Monday for the development of a non-antiretroviral-based compound to block HIV and other sexually transmitted infections could yield a low-risk, easy access product for women in low resource settings in as few as a dozen years, if a promising new compound performs as hoped. That is a big if - the field of microbicide research has seen a roller coaster of raised expectations and dashed hopes over the last decades.

    11 January 2014 | Science Speaks
  • AAPS showcases vaginal ring with tenofovir + contraceptive, gel suitable for vaginal and rectal use

    A new intravaginal ring delivers both tenofovir for HIV prevention and levonorgestrel for contraception for 3 months, researchers reported at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition taking place this week in San Antonio. Other studies looked at a novel gel for both vaginal and rectal use containing the antiretroviral IQP-0528, and a bio-adhesive vaginal gel combining tenofovir and the anti-herpes drug acyclovir.

    21 November 2013 | HIVandHepatitis.com
  • Novel microbicide gel for vagina and rectum shows potential for HIV prevention

    Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus. The DuoGel will deliver ImQuest's antiretroviral compound IQP-0528.

    15 November 2013 | Eurekalert Inf Dis
  • HIV Microbicides Require Safety, Efficacy, Good Marketing

    Designing a successful topical microbicide against HIV must balance efficacy and toxicity. Microbicides are intended to cut down the risk for transmission of HIV, and they may give a measure of control to people whose partners do not use condoms.

    30 October 2013 | Medscape (requires free registration)
  • IPM Receives Two Awards from USAID to Advance HIV Prevention Technologies for Women

    The International Partnership for Microbicides (IPM) announced today that it has received two competitive five-year awards with a combined US$40 million ceiling from the US Agency for International Development (USAID). Both awards aim to advance new HIV prevention tools for women and to help ensure their availability in developing countries where the epidemic has hit hardest.

    22 October 2013 | International Partnership for Microbicides
  • Researchers launch first-ever phase II safety study of rectal microbicide to prevent HIV

    Taking an important step toward the development of a product to prevent HIV infections associated with unprotected anal sex, researchers today announced the launch of a global Phase II clinical trial of a potential rectal microbicide. The trial, led by the US National Institutes of Health-funded Microbicide Trials Network, is testing the rectal use of a reduced glycerin gel formulation of the antiretroviral drug tenofovir.

    03 October 2013 | Eurekalert Inf Dis
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.